Editas Medicine is dedicated to the discovery and development of a new class of therapeutic agents for genome editing. The company has filed a large of patent applications and has access to intellectual property covering major genome editing technologies, as well as significant advances and capabilities that will uniquely enable the company to translate early discoveries into viable therapeutic products for humans.
Editas Medicine's mission is to transform its genome editing technology into a new class of human therapies that allow precise and corrective molecular modification to treat the underlying cause of a wide range of diseases at the genetic level.
In December 2020, Editas shares jumped 50% as ARK INNOVATION ETF ( ARKK ) founder and manager Katy Wood believes genomic stocks will generate huge returns over the next 5 years.
For the past couple of years, a sort of musical chair game has been going on among the leaders of Editas Medicine (NASDAQ: EDIT). In February of this year, the company announced the departure of its CEO and immediately named a replacement.
IMHO, the current management team will be able to lead the company to new successes, and we will hear about this company more than once from all the successors. Until December 31st, the company will have the results of the Clinical Trial of the following candidates for the Natural History Study of CEP290-Related Retinal Degeneration:
- Leber Congenital Amaurosis 10
- Vision Disorders
- Eye Diseases
- Eye Diseases, Hereditary
- Eye Disorders Congenital
- Retinal Disease
- Retinal Degeneration
I believe in EDIT to go up to 110$ next year/